Journal Mobile Options
Table of Contents
Vol. 81, No. 3-4, 2011
Issue release date: December 2011
Oncology 2011;81:206–213
(DOI:10.1159/000333095)

Clinicopathologic Outcomes of Curative Resection for Sarcomatoid Carcinoma of the Lung

Park J.S. · Lee Y. · Han J. · Kim H.K. · Choi Y.S. · Kim J. · Shim Y.M. · Kim K.
Departments of aThoracic and Cardiovascular Surgery, and bPathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, and cDepartment of Thoracic and Cardiovascular Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Sarcomatoid carcinoma of the lung is a very rare and aggressive subtype of non-small cell lung cancer. We explored the clinicopathologic characteristics and surgical outcome of this tumor. Methods: Among 4,212 patients who underwent curative resection for non-small cell lung cancer from September 1994 to December 2009, 99 patients had sarcomatoid carcinoma. Medical records of patients were reviewed retrospectively. Results: The mean follow-up period was 16.07 months. Thirty-six patients had pathologic stage I disease, and 63 had more advanced disease. Surgery included 2 wedge resections, 67 lobectomies, 17 bilobectomies, and 13 pneumonectomies. There were 90 pleomorphic carcinomas, 6 spindle cell carcinomas, 1 giant cell carcinoma, 1 carcinosarcoma, and 1 pulmonary blastoma. Overall 5-year survival was 54.3%. Forty-three patients experienced recurrence and 42 of these died of the cancer. Pathologic T stage as defined by the 7th TNM staging system was significantly associated with survival and recurrence (p = 0.004 and 0.002, respectively). Mean positron emission tomography uptake was significantly higher than in other types of lung cancer (p < 0.0001). Conclusions: Our results implied that surgery for sarcomatoid carcinoma must be carefully planned after extensive preoperative evaluation. Efforts should be made for accurate preoperative histological diagnosis of large peripheral tumor with exceedingly high positron emission tomography uptake.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, Viale G, Rosai J: Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103–120.
  2. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN: Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994;73:2936–2945.
  3. Ro JY, Chen JL, Lee JS, Sahin AA, Ordonez NG, Ayala AG: Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992;69:376–386.
  4. Matsui K, Kitagawa M: Spindle cell carcinoma of the lung. A clinicopathologic study of three cases. Cancer 1991;67:2361–2367.
  5. Matsui K, Kitagawa M, Miwa A: Lung carcinoma with spindle cell components: sixteen cases examined by immunohistochemistry. Hum Pathol 1992;23:1289–1297.
  6. Tsubota YT, Kawaguchi T, Hoso T, Nishino E, Travis WD: A combined small cell and spindle cell carcinoma of the lung. Report of a unique case with immunohistochemical and ultrastructural studies. Am J Surg Pathol 1992;16:1108–1115.
  7. Wick MR, Ritter JH, Nappi O: Inflammatory sarcomatoid carcinoma of the lung: report of three cases and clinicopathologic comparison with inflammatory pseudotumors in adult patients. Hum Pathol 1995;26:1014–1021.
  8. Terzi A, Gorla A, Piubello Q, Tomezzoli A, Furlan G: Biphasic sarcomatoid carcinoma of the lung: report of 5 cases and review of the literature. Eur J Surg Oncol 1997;23:457.
  9. Nappi O, Glasner SD, Swanson PE, Wick MR: Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of ‘carcinosarcomas’ and ‘spindle-cell carcinomas’. Am J Clin Pathol 1994;102:331–340.
  10. Nappi O, Wick MR: Sarcomatoid neoplasms of the respiratory tract. Semin Diagn Pathol 1993;10:137–147.
  11. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059–1068.
  12. Beasley MB, Brambilla E, Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90–97.
  13. Franks TJ, Galvin JR: Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med 2010;134:49–54.

    External Resources

  14. Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC: Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 2007;84:973–980.
  15. Yuki T, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M: Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg 2007;134:399–404.
  16. Travis WD: Pathology of lung cancer. Clin Chest Med 2002;23:65–81, viii.
  17. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 1995;75:191–202.
  18. Koss MN, Hochholzer L, Frommelt RA: Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol 1999;23:1514–1526.
  19. Koss MN, Hochholzer L, O’Leary T: Pulmonary blastomas. Cancer 1991;67:2368–2381.
  20. Yousem SA, Hochholzer L: Mucoepidermoid tumors of the lung. Cancer 1987;60:1346–1352.
  21. Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti- EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125:2479–2482.
  22. Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N: Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010;5:460–465.
  23. Leone A, Graziano P, Gasbarra R, Paone G, Cardillo G, Mancuso A, De Marinis F, Ricciardi S, Portalone L, Pisa R: Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2010;128:732–735, author reply 736.

    External Resources

  24. Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010;68:204–210.
  25. Kim TH, Kim SJ, Ryu YH, Lee HJ, Goo JM, Im JG, Kim HJ, Lee DY, Cho SH, Choe KO: Pleomorphic carcinoma of lung: comparison of CT features and pathologic findings. Radiology 2004;232:554–559.
  26. Ishida T, Tateishi M, Kaneko S, Yano T, Mitsudomi T, Sugimachi K, Hara N, Ohta M: Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg 1990;100:844–852.
  27. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N: Biologic correlates of (1)F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer 2011;71:144–150.
  28. Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab HS, De Manzoni G, Terzi A, Viale G: Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003;27:1203–1215.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50